TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market Hours

Key Takeaways Tempus AI's Q3 loss of 11 cents per share beat estimates, with revenues up 84.7% year over year. TEM's Genomics revenues rose 117.2%, led by strong oncology and hereditary testing volume growth. Tempus AI lifted 2025 revenue and EBITDA guidance, despite an unchanged operating loss. Tempus AI, Inc. (TEM) reported a third-quarter 2025 adjusted loss of 11 cents per share, narrower than the Zacks Consensus Estimate by 31.3%.GAAP loss per share was 46 cents, flat on a year-over-year basis. TEM’s Q3 ...